Literature DB >> 20519552

Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1).

Yurong Lai1, Kathleen E Sampson, Larissa M Balogh, Timothy G Brayman, Steven R Cox, Wade J Adams, Vikas Kumar, Jeffrey C Stevens.   

Abstract

N-({(5S)-3-[4-(1,1-dioxidothiomorpholin-4-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide (PNU-288034), an oxazolidinone antibiotic, was terminated in phase I clinical development because of insufficient exposure. Analysis of the drug pharmacokinetic and elimination profiles suggested that PNU-288034 undergoes extensive renal secretion in humans. The compound was well absorbed and exhibited approximately linear pharmacokinetics in the oral dose range of 100 to 1000 mg in human. PNU-288034 was metabolically stable in liver microsomes across species, and unchanged drug was cleared in the urine by an apparent active renal secretion process in rat and monkey (two to four times glomerular filtration rate) but not dog. In vitro studies conducted to characterize the transporters involved demonstrated PNU-288034 uptake by human organic anion transporter 3 (OAT3; K(m) = 44 +/- 5 microM) and human multidrug and toxin extrusion protein 1 (hMATE1; K(m) = 340 +/- 55 microM). The compound was also transported by multidrug resistance P-glycoprotein and breast cancer resistance protein. In contrast, human organic cation transporter 2, human OAT1, and hMATE2-K did not transport PNU-288034. Coadministration of PNU-288034 and the OAT3 inhibitor probenecid significantly increased PNU-288034 plasma area under the curve (170%) and reduced both plasma and renal clearance in monkey. Coadministration of PNU-288034 and cimetidine, a MATE1 inhibitor, also reduced plasma clearance in rat to a rate comparable with probenecid coadministration. Collectively, our results demonstrated a strong in vitro-in vivo correlation for active renal secretion coordinated through the vectorial transport process of OAT3 and MATE1, which ultimately resulted in limiting the systemic exposure of PNU-288034.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20519552     DOI: 10.1124/jpet.110.170753

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters.

Authors:  David J Wagner; Jennifer E Sager; Haichuan Duan; Nina Isoherranen; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2017-04-20       Impact factor: 3.922

Review 2.  Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease.

Authors:  Li Wang; Douglas H Sweet
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Renal excretion of apricitabine in rats: ex vivo and in vivo studies.

Authors:  Mariana Babayeva; Susan Cox; Michael P White; David R Taft
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-04-06       Impact factor: 2.441

Review 5.  Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics.

Authors:  Atsushi Yonezawa; Ken-ichi Inui
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

6.  Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.

Authors:  Yeamin Huh; David E Smith; Meihau Rose Feng
Journal:  Xenobiotica       Date:  2011-09-05       Impact factor: 1.908

7.  Multiple Drug Transporters Are Involved in Renal Secretion of Entecavir.

Authors:  Xi Yang; Zhiyuan Ma; Sisi Zhou; Yayun Weng; Hongmei Lei; Su Zeng; Liping Li; Huidi Jiang
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 8.  Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics.

Authors:  David J Wagner; Tao Hu; Joanne Wang
Journal:  Pharmacol Res       Date:  2016-06-16       Impact factor: 7.658

9.  The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics.

Authors:  Birui Shi; Yan Zhang; Baolin Huang; Huiping Lin; Qiong Zhou; Yujue Wang; Zheng Cai; Menghua Liu
Journal:  Molecules       Date:  2022-01-21       Impact factor: 4.411

10.  Identification of Structural Features for the Inhibition of OAT3-Mediated Uptake of Enalaprilat by Selected Drugs and Flavonoids.

Authors:  Yao Ni; Zelin Duan; Dandan Zhou; Shuai Liu; Huida Wan; Chunshan Gui; Hongjian Zhang
Journal:  Front Pharmacol       Date:  2020-05-28       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.